The Turku-based DelSiTech, a drug delivery and drug development company, announces that it has been awarded a grant from the Bill & Melinda Gates Foundation.
- DelSiTech Ltd. develops biodegradable silica-based controlled release of small molecule drugs, biologics, and viral vectors. DelSiTech also provides super generic drug products for significant unmet medical and market needs.
- DelSiTech Silica Matrix is an advanced delivery technology platform for parenteral and local administration of injectable and implant dosage forms, as well as eye drops. The resulting Silica Matrix is non-porous, biocompatible, and can be designed to biodegrade by matrix dissolution at the desired rate to ensure a tightly controlled release of the active substance over periods of days up to many months or a year.
- This funding marks the third grant awarded from the Bill & Melinda Gates Foundation to DelSiTech since 2018. In December 2022 the foundation provided $800,000 for Warsaw-based developer of mRNA vaccines and therapeutics ExPLoRNA Therapeutics.
- The grant will be used to develop long-acting injectable formulations, ensuring the slow release of human immunodeficiency virus (HIV) vaccine.
